Compass Therapeutics — Q3 2026 Earnings Summary

Compass Therapeutics reported a net loss of $27.2 million for the third quarter of 2026, driven primarily by increased research and development expenses related to tovecimig manufacturing. The company is advancing preparations for a Biologics License Application submission for tovecimig in biliary tract cancer patients, despite an FDA recommendation for an additional survival study. Clinical data from the COMPANION-002 study published in the Journal of Clinical Oncology demonstrated statistically significant improvements in objective response rate and progression-free survival for tovecimig combined with paclitaxel. Compass Therapeutics holds $163 million in cash and marketable securities as of September 30, 2026, which is projected to fund operations through 2028 while continuing enrollment in Phase 1 and Phase 2 trials for its other pipeline assets.